An interventional study of Sebutape sampling and Bacitracin/Polymyxin B/Neomycin ointment (Yentuogin ointment) in Acne, Atopic Dermatitis and Seborrheic Dermatitis, sponsored by National Taiwan University Hospital. Not yet recruiting. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Basic science
This study aims to develop a standardized workflow for sebum sampling and metabolomics/lipidomics analysis using Sebutape. A total of 200 participants will be recruited, including healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention. The study will investigate sebum composition, skin microbiome profiles, and their interactions under different conditions to explore potential biomarkers and clinical applications.
This study focuses on establishing a comprehensive Sebutape-based workflow for sebum metabolomics and lipidomics, including standardized sampling and extraction procedures and optimization of an LC-MS/MS pseudotargeted analytical platform. Sebutape samples will be collected from 200 participants across four groups: healthy individuals, patients with skin diseases or specific skin conditions, individuals undergoing dermatological treatments or using skincare products, and healthy participants receiving short-term topical antibiotic intervention. Each sample will be analyzed for lipidomic and metabolomic profiles, while parallel microbiome profiling will be performed using 16S rRNA sequencing. The study aims to evaluate reproducibility, analytical reliability, and lipid-microbe interactions, thereby identifying candidate biomarkers and elucidating pathogenic mechanisms in skin disorders.
A. Healthy Participants
Inclusion Criteria:
Exclusion Criteria:
B. Participants with Skin Diseases or Specific Skin Conditions
Inclusion Criteria:
Diagnosed by a physician or clinically assessed as having one of the following:
Exclusion Criteria:
C. Participants Receiving Dermatological Treatments or Using Skincare Products
Inclusion Criteria:
Participants who, based on clinical needs or daily routines, are currently using or are expected to use or receive any of the following:
Exclusion Criteria:
D. Healthy Participants Undergoing Short-term Antibiotic Intervention
Inclusion Criteria:
Exclusion Criteria:
All participants will undergo non-invasive sebum sampling using Sebutape. Samples will be analyzed for metabolomic and lipidomic profiles using LC-MS/MS, and microbiome profiling will be performed using 16S rRNA sequencing. Subgroups include healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention.
Other: Sebutape sampling · Drug: Bacitracin/Polymyxin B/Neomycin ointment (Yentuogin ointment)
Non-invasive sebum sampling using Sebutape patches. Each participant will undergo standardized sampling procedures, with one patch used for metabolomics/lipidomics analysis and another for microbiome profiling. Samples will be stored at -80 °C for subsequent LC-MS/MS and 16S rRNA sequencing.
Short-term topical antibiotic intervention using Yentuogin ointment containing Bacitracin, Polymyxin B, and Neomycin. Healthy participants will apply the ointment 1-2 times daily for up to 3 days. Sebutape samples will be collected before and after intervention to assess changes in sebum composition and skin microbiome.
Concentration of Sebum Lipids Measured by LC-MS/MS
Sebum lipid levels will be measured using Sebutape sampling followed by LC-MS/MS analysis. Results will be reported as normalized intensity.
Time frame: From baseline (pre-intervention or pre-treatment) to post-intervention (approximately 1 day after completion of a 3-day intervention) or post-treatment (up to 3 months after treatment initiation, depending on treatment regimen)
Relative Abundance of Skin Microbiome Composition Assessed by Sequencing
Skin microbiome profiles will be assessed using sequencing-based analysis and reported as relative abundance (%).
Time frame: From baseline (pre-intervention or pre-treatment) to post-intervention (approximately 1 day after completion of a 3-day intervention) or post-treatment (up to 3 months after treatment initiation, depending on treatment regimen)
No study locations are listed for this record.
Plan to share: No — There are no plans to share individual participant data due to ethical considerations and privacy concerns. Only aggregated results will be published.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital